Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ Π΄ΠΈΡΡΠ΅ΠΌΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° ΡΠ΅ΠΉΠΊΠΈ ΠΌΠ°ΡΠΊΠΈ
ΠΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ ΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ ΡΡ Π΅ΠΌ Ρ ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ, ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΠΌΡΡ Π² ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π΄ΠΈΡΡΠ΅ΠΌΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° ΡΠ΅ΠΉΠΊΠΈ ΠΌΠ°ΡΠΊΠΈ ΠΎΡΡΡΠ΅ΡΡΠ²Π»Π΅Π½ΠΎ Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠΉ Π·Π° Π±ΠΎΠ»ΡΠ½ΡΠΌΠΈ, Π½Π°Ρ ΠΎΠ΄ΠΈΠ²ΡΠΈΠΌΠΈΡΡ Π½Π° ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π² ΠΎΡΠ΄Π΅Π»Π΅Π½ΠΈΠΈ Π±ΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΠΊΠΎΡΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° ΠΠΠ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈΠΌ. ΠΏΡΠΎΡ. Π. Π. ΠΠ΅ΡΡΠΎΠ²Π° Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ Ρ 1998 Π³ΠΎΠ΄Π° ΠΏΠΎ 2005 Π³ΠΎΠ΄Π°. Π ΡΠ°Π±ΠΎΡΡ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΎ 73 Π±ΠΎΠ»ΡΠ½ΡΡ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ°ΠΊΠΎΠΌ ΡΠ΅ΠΉΠΊΠΈ… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- ΠΠΊΡΠ΅Π»Ρ Π.Π., ΠΠ°Π²ΡΠ΄ΠΎΠ² Π. Π. Π‘ΡΠ°ΡΠΈΡΡΠΈΠΊΠ° Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΠΈ ΠΈ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΠΈ ΠΎΡ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ Π² 2000 Π³ΠΎΠ΄Ρ // ΠΠ»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠ΅ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ Π² Π ΠΎΡΡΠΈΠΈ ΠΈ ΡΡΡΠ°Π½Π°Ρ Π‘ΠΠ Π² 2000. ΠΠΎΡΠΊΠ²Π°: Π ΠΠΠ¦ ΠΈΠΌ. Π. Π. ΠΠ»ΠΎΡ ΠΈΠ½Π° Π ΠΠΠ. — 2002. — Π‘. 85−106.
- ΠΠΎΡ ΠΌΠ°Π½ Π―.Π. ΠΠ»ΠΈΠ½ΠΈΠΊΠ° ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΡΠ°ΠΊΠ° ΡΠ΅ΠΉΠΊΠΈ ΠΌΠ°ΡΠΊΠΈ // ΠΠΈΡΠΈΠ½Π΅Π²: Π¨ΡΠΈΠΈΠ½ΡΠ°.- 1976. Π‘. 169−177.
- ΠΠΎΡ ΠΌΠ°Π½ Π―.Π. Π ΡΠΊΠΎΠ²ΠΎΠ΄ΡΡΠ²ΠΎ ΠΏΠΎ ΠΎΠ½ΠΊΠΎΠ³ΠΈΠ½Π΅ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ Π.: ΠΠ΅Π΄ΠΈΡΠΈΠ½Π°. — 1989. — Π‘. 195−199.
- ΠΠΎΡ ΠΌΠ°Π½ Π―.Π., ΠΡΡΡΠ° Π£. Π. Π Π°ΠΊ ΡΠ΅ΠΉΠΊΠΈ ΠΌΠ°ΡΠΊΠΈ // ΠΠΈΡΠΈΠ½Π΅Π²: Π¨ΡΠΈΠΈΠ½ΡΠ°.-1991.-Π‘. 239.
- ΠΠ°ΡΠΈΠ½ A.M. Π Π’Π°ΠΊΡΠΎΡΠ΅ΡΠ΅, ΠΠ°ΠΌΠΏΡΠΎ ΠΈ ΠΡΠ°Π½ΠΎΡΠΈΡΠ΅ Π. — 1997. Π‘. 26−45.
- ΠΠ»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠ΅ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ Π² Π ΠΎΡΡΠΈΠΈ Π² 1999 Π³ΠΎΠ΄Ρ (Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΡ ΠΈ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΡ). // ΠΠΎΠ΄ ΡΠ΅Π΄. Π. Π. Π§ΠΈΡΡΠΎΠ²Π°, Π. Π. Π‘ΡΠ°ΡΠΈΠ½ΡΠΊΠΎΠ³ΠΎ. ΠΠΎΡΠΊΠ²Π° — 2000.
- ΠΠΎΠ½Π΄ΡΠ°ΡΡΠ΅Π² Π.Π., ΠΠ°ΡΠ°ΡΡΠ²Π° Π. Π. ΠΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΈ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ° ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Ρ ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ ΠΏΠ»Π°ΡΠΈΠ½Ρ ΠΈ ΡΠ°ΠΊΡΠ°Π½Π°ΠΌΠΈ // ΠΡΠ°ΠΊΡΠΈΡ. ΠΠ½ΠΊΠΎΠ». -2000. -№ 3.- Π‘. 38−42.
- ΠΡΠΏΡΡΠΊ 5. ΠΠ΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΠ΅ ΡΡΠ΅Π΄ΡΡΠ²Π°, ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΠΌΡΠ΅ Π² ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ // Π.: Π Π¦ «Π€Π°ΡΠΌΠ΅Π΄ΠΈΠ½ΡΠΎ». 1999. — Π‘.54−61.
- ΠΠΎΠ²ΠΈΠΊ Π.Π. ΠΠΏΠΈΠ΄Π΅ΠΌΠΈΠΎΠ»ΠΎΠ³ΠΈΡ ΡΠ°ΠΊΠ° ΡΠ΅ΠΉΠΊΠΈ ΠΌΠ°ΡΠΊΠΈ, ΡΠ°ΠΊΡΠΎΡΡ ΡΠΈΡΠΊΠ°, ΡΠΊΡΠΈΠ½ΠΈΠ½Π³// ΠΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡ 2002. — Π’. Π, № 3. — Π‘. 157.
- ΠΠ΅ΡΠ΅Π²ΠΎΠ΄ΡΠΈΠΊΠΎΠ²Π° Π.Π. ΠΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ ΠΎΠ»Π΅Π²Π°Ρ Ρ ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ. ΠΠΎΡΠΊΠ²Π°. 1986.
- ΠΡΠΈΠ»Π΅ΠΏΡΠΊΠ°Ρ Π.Π., ΠΠΎΠ½Π΄ΡΠΈΠΊΠΎΠ² Π. Π., ΠΠ΅Π±Π½Π΅Π²Π° Π’. Π. ΠΠΈΠ½Π΅ΠΊΠΎΠ»ΠΎΠ³ΠΈΡ Π΄Π»Ρ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈΡ Π²ΡΠ°ΡΠ΅ΠΉ // 2000. Π’.2, № 3. — Π‘. 80−82.
- Π Π΅ΠΌΠ΅Π½Π½ΠΈΠΊ JI.B., ΠΠΎΠ²ΠΈΠΊΠΎΠ²Π° Π. Π., ΠΠΎΠΊΠΈΠ½Π° Π. Π. ΠΈ Π΄Ρ. ΠΠ»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠ΅ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ ΠΆΠ΅Π½ΡΠΊΠΈΡ ΠΏΠΎΠ»ΠΎΠ²ΡΡ ΠΎΡΠ³Π°Π½ΠΎΠ² Π² Π ΠΎΡΡΠΈΠΈ // Π ΠΎΡ. ΠΠ½ΠΊΠΎΠ». ΠΡΡΠ½. 1997. — № 6. — Π‘. 4−8.
- Π ΠΎΡΠ΅Π½Π±Π΅ΡΠ³ M.JI. Π‘Π Π’ 11: Π½ΠΎΠ²ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΈ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΡΠΈ ΡΠ°ΠΊΠ΅ ΡΠΎΠ»ΡΡΠΎΠΉ ΠΈ ΠΏΡΡΠΌΠΎΠΉ ΠΊΠΈΡΠΊΠΈ ΠΈ Π΄ΡΡΠ³ΠΈΡ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡΡ // Oncologist. — 2001. — № 6 — Π‘.66−80.
- Π’ΡΠ°ΠΏΠ΅Π·Π½ΠΈΠΊΠΎΠ² Π.Π., ΠΠΊΡΠ΅Π»Ρ Π. Π., ΠΠ°ΡΠΌΠΈΠ½Π° Π. Π., «Π‘ΠΎΡΡΠΎΡΠ½ΠΈΠ΅ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠΎΡΠΈ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ ΡΡΡΠ°Π½ Π‘ΠΠ Π² 1996 Π³ΠΎΠ΄Ρ». // ΠΠΎΡΠΊΠ²Π°: ΠΠΠ¦ Π ΠΠΠ. 1997. — Π‘. 192.
- Π’ΡΡΡΠΈΠ½Π° Π.Π., ΠΠΎΠ²ΠΈΠΊΠΎΠ²Π° Π. Π. «Π ΠΎΠ»Ρ ΠΏΠ°ΠΏΠΈΠ»Π»ΠΎΠΌΠ°Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π² Π³Π΅Π½Π΅Π·Π΅ ΡΠ°ΠΊΠ° ΡΠ΅ΠΉΠΊΠΈ ΠΌΠ°ΡΠΊΠΈ». // Π ΠΎΡ. ΠΠ½ΠΊΠΎΠ». ΠΡΡΠ½Π°Π». — 2005. -№ 1. -Π‘. 4551.
- Π₯Π°Π½ΡΠΎΠ½ Π.Π., ΠΠΌΡΠ½ΠΈΡΠΎΠ² Π. Π. «Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΎ ΠΊΠ°Π½ΡΠ΅ΡΠΎΠ³Π΅Π½Π΅Π·Π΅ ΡΠ°ΠΊΠ° ΡΠ΅ΠΉΠΊΠΈ ΠΌΠ°ΡΠΊΠΈ» // ΠΡΠ°ΠΊΡΠΈΡ. ΠΠ½ΠΊΠΎΠ». 2002. — Π’.Π. № 3. — Π‘. 145−155.
- Π§ΠΈΡΡΠΎΠ² Π.Π. Π‘ΠΎΡΡΠΎΡΠ½ΠΈΠ΅ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠΎΡΠΈ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ Π ΠΎΡΡΠΈΠΈ Π² 2000 Π³ΠΎΠ΄Ρ//Π. 2001. — Π‘. 92.
- Π§ΠΈΡΡΠΎΠ² Π.Π., Π‘ΡΠ°ΡΠΈΠ½ΡΠΊΠΈΠΉ Π. Π., Π Π΅ΠΌΠ΅Π½Π½ΠΈΠΊ JI.B. — «ΠΠ»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠ΅ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ Π² Π ΠΎΡΡΠΈΠΈ Π½Π°ΠΊΠ°Π½ΡΠ½Π΅ XXI Π²Π΅ΠΊΠ°, ΠΊΠ°ΠΊ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ°Ρ ΠΈ ΡΠΎΡΠΈΠ°Π»ΡΠ½Π°Ρ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ°». // Π ΠΎΡ. ΠΠ½ΠΊΠΎΠ». ΠΡΡΠ½Π°Π». 1998. — № 3. — Π‘. 8−20.
- Π§ΠΈΡΡΠΎΠ² Π.Π., Π‘ΡΠ°ΡΠΈΠ½ΡΠΊΠΈΠΉ Π. Π., ΠΠ΅ΡΡΠΎΠ²Π° Π. Π. «ΠΠ»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠ΅ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ Π² Π ΠΎΡΡΠΈΠΈ Π² 2002 Π³ΠΎΠ΄Ρ (Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΡ ΠΈ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΡ)» // ΠΠΎΡΠΊΠ²Π°. 2004.
- Π¨Π΅Π»Π΅ΡΡΡΠΊ Π.Π., Π€ΡΠΎΠ»ΠΎΠ² Π. Π€., ΠΠ΅Π³ΠΎΡΠ»ΠΎΠ² Π. Π. ΠΈ Π΄Ρ. ΠΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΎΠ±ΡΡΠ°Π½ΠΎΠ²ΠΊΠ° ΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΡ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌΠΈ ΠΎΠΏΡΡ ΠΎΠ»ΡΠΌΠΈ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ ΠΠ‘Π‘Π . // ΠΠ΅ΡΡΠ½ΠΈΠΊ ΠΠΎΡΠ΄ΠΎΠ²ΡΠΊΠΎΠ³ΠΎ ΡΠ½-ΡΠ°.- 1993. № 2. — Π‘.46−48.
- Abigerges D., Armand J.P., Chabot G.G. et al. Irinotecan (cpt-11) high-dose ecscalation using intensive high-dose loperamide to control diarrhea // J. Nat. Cancer Inst. 1994. — Vol. 86. — P. 446−449.
- Adlard J.W., Richman S.D., Seymour M.T. et al. Prediction of the response of colorectal cancer to systemic therapy // The Lancet Oncology. -2002.-Vol.3.-P. 75−82.
- Andoh Π’., Ishii K., Suzuki Y. et al. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I // Proc. Natl. Acad. Sci USA. 1987. — Vol. 84. — P. 5565−5569.
- Aogi K., Nishiyama M., Kim R. et al. Overcoming CPT-11 resistance by using a biscocdaurine alkaloid, cepharanthine to modulate plasmatrans-membrane potential // Int. J. Cancer. 1997. — Vol. 72. — P. 29.
- Armand J.P., Ducreux M., Mahjoubi M. et al. CPT-11 (irinotecan) in the treatment of colorectal cancer. // Eur. J. Cancer. 1995. — Vol. 31 A. — P. 1283−1287.
- Arseneau J, Blessing J, Stehman F, et al. A phase II study of carboplatin in advanced" squamous cell carcinoma of the cervix. // Invest. New Drugs. -1986.-Vol. 4. -P.187−191.
- Baker L., Boutselis J., Alberts D. et al. Combination chemotherapy for patients with disseminated carcinoma of the uterine cervix. // Proc. ASCO. 1985.-Vol. 4.-P. 120
- Banga H., Banken L., Burger H-U. et al. A phase I study of continuous twice daily oral therapy with Ro 09−1978 in patients with advanced and/or metastatic solid tumor (Protocol SO 14 693) // Res. Rep. 1997. — N-139 256.
- Bissery M. C, Mathieu-Boue A., Lavelle F. Experimental antitumor activity of CPT-11 in vitro and in vivo // 7th NCI-EORTC Symp. On New Drugs in Cancer Therapy. 1992. — Abstr. 093.
- Bissery M. C, Mathieu-Boue A., Lavelle F. Preclinical evaluation of CPT-11, a camptotethin derivative. // ASCO. 1991. — Abstr.2389.
- Boisseau M., Guichard S., Canal P., Bugat R. Irinotecan (Π‘Π Π’ 11): current status and perspectives // Exp. Opin. Invest. Drugs. 1996. Vol. 5. — P. 613−626.
- Bonadonna G., Valagussa P., Moliterni A. et al: Adjuvant cyclophosphamide, methotrexate and 5-fluorouracil in node positive breast cancer, the results of 20 years follow-up. // N. Engl. J. Med. 1995. — Vol. 14.-P. 332−341.
- Bonomi P., Blessing J. A., Stehman F. et al. Rondomized of three cisplatin doze schedules in squamous-cell carcin of the cervix: A Gynecologic Oncology Group Study. // J. Clin. Oncol. 1985. — Vol. 3. — P.1079 -1085.
- Bouzid K., Mahfouf H. A study with gemcitabine (G) and cisplatin © in locally advanced, recurrent or metastatic squamous cell carcinoma of the cervix. // Proc. ASCO 2000. — Vol. 19. — P 391a. — Abstr. 1549.
- Brader K.R., Morris M., Levenbach C. et al. Chemotherapy of cervical carcinoma. Factors determining response and implications for clinical trial design. //J. Clin. Oncol. 1998. — Vol. 16. — P. 1879−1884.
- Brader K.R., Morris M., Levenback C. et.al. Chemotherapy for cervical carcinoma: factors determing response and implications for clinical trial design // J. Clin. Oncol. 1998. — Vol. 16. — P. 1879−1884.
- Burnett A., Roman L., Garcia A. A phase II study of gemcitabine and cisplatin in patients with advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study // Gynecol. Oncol. 2000. -Vol.76, № 1.-P.63- 66.
- Capizzini R.L. Amifostine reduced the incidence of cumulative nephrotoxicity from cisplanin: Laboratory and clinical aspects // Semin. Oncol. 1999. — Vol.26 (Suppl.7). — P. 72−81.
- Cartwright Π’.Π., Cohn A., Varkey J.A. et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer // J. Clin. Oncol. 2001. — Vol. 20. — P. 160−164.
- Cavin S.J., Geisler H. Treatment of advanced, unresectable, cervical carcinoma already subjected to complete irradiation therapy // Gynecol. Oncol. 1978. — Vol. 6. — P.256−260.
- Chabot G.G., Abigerges D., Catimel G. et al. Population pharmacokinetics and pharmacodynamics of irinotecan (cpt-11) and active metabolite SN-38 during Phase I trials // Ann. Oncol. 1995. — Vol. 6. — P. 141−151.
- Chevallier Π., Lhomme C., Dieras V. et al., Phase II trial of CPT-11 in advanced cervical carcinoma // ASCO. 1995. — Abstr. 737.
- Chitapanarux I., Tonusin A., Sucthomya V. et al. Phase II study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer // Gynecol. Oncol. 2003. — Vol. 89, № 3. P. 402−407.
- Chlebowski R.T., Pugh R.P., Weiner J.M. et al. Treatment of advanced breast cancer with 5-fluorouracil: a randomized comparison of two routes of delivery// Cancer. 1981. -Vol. 48. — P. 1711−1714.
- Chu X.Y., Suzuki H, Ueda Π et al. Active efflux of CPT-1 land its metabolites in human KB-derived cell lines // J. Pharmacol Exp. Ther. -1999. Vol. 288. — P.735−741.
- Cohen C.J., Castro-Martin A, Deppe G, Bruckner HW, Hollad JF. Chemotherapy of advanced recurrent cervical cancer with platinum II-preliminaiy report // ASCO. 1978. — Abstr. C-379. — P. 401.
- Curtin J., Lanciano R.M., Kudelka A.P. Cervical cancer. / In: «Cancer Managements». A Multidisciplinary Approach Pazdur R. (eds.) et al. — 1998.-P. 149−173.
- Cvitkovit E., Droz J.P., Kattan J., Ghosn M. Cisplatin / In: «Handbook of Chemotherapy in Clinical Oncology». Eds. Cvitkovit E. et al. // 1993. P. 242−245.
- Danenberg K., Metzger R., Groshen S. et al. Thymidylate synthase and thymidine phosphorylase are prognostic indicators of survival for colorectal cancer // Proc. ASCO. 1997. — Vol. 16. — P. 237a (abstr. 914).
- Diaz-Rubio E., Evans T.R.J., Tabernero J. et al. Capecitabine (Xeloda) in combination with Oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors // Ann. Oncol. 2002.- Vol. 13. -P. 558−565.
- Domingo E.J. // ESMO. 2000. — Abstr. 397P.
- Endicott J.A., Ling U. The biochemistry of P-glycoprotein-median multidrug resistance // Ann. Rev. Bioch. 1989. — Vol. 58. — P. 137.
- Fabian C.J., Molina R., Slavik M. et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion // Invest. New Drugs.- 1990.- Vol. 8.- P. 57.
- Ferlay J., Bray F., Pisani P., Parkin D.M. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide // Lyon: IARC Press. -2001.-P. 35−37.
- Findlay M., E. Van Gutsen, Kocha W. et al. A randomized phase II study of Xeloda (capecitabine) in patients with advanced colorectal cancer. // Proc. ASCO. 1997. — Vol.16. — abstr.790.
- Fisher B. What is early breast cancer // Early breast cancer. Ed. by J. Zander and J. Baltzer. — Berlin etc.: Springer-Verlag. — 1985.
- Freeman R, Herson J, Wharton T, et al. Single agent chemotherapy for recurrent carcinoma of the cervix. // Cancer Clin. Trials. — 1980. Vol. 3. -P.345−350.
- Friedlander M. Guidelines for the treatment of recurrent and metastatic cervical cancer// Oncologist. 2002. — Vol. 7. — P. 342−347.
- Fujimori A., Harker W.G., Kohlhagen G. et al. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin // Cancer Res. 1995. — Vol. 55. — P. 1339−1346.
- Furuta Π’., Yokokura T. Combination therapy of CPT-11, a camptothecin derivate, with various antitumor drugs against. L 1210 Leukemia // Jpn. Cans. Chem. 1991. — Vol. 18. — P.393−402.
- Gandia D., Abigerges D., Armand J.P., et al. CPT-11 induced cholinergic effects in cancer patients // J. Clin. Oncol. 1993. — Vol. 11. — P. 196−197.
- Goldie J.H. Drug resistance / In: «Chemotherapy source book» Perry M.C. (Eds.) 1992.-P.54−66.
- Goldie J.H., Coldman A.J. The genetic origin of drug resistance in neoplasms: implications for systemic therapy // Cane. Res. 1984. — Vol. 44.-P. 3643−3653.
- Greenlee R., Murray Π’., Bolden S., et al. Cancer statistics, 2001. // CA Cancer J. Clin. 2001. — Vol. 36. — P. 5115.
- Grem J.L. 5-Fluoropyrimidines. In Cancer Chemotherapy and Biotherapy: Principles and Practice / 2nd ed. By Chabner B.A., Longo D.L. -Lippincott-Raven Pub. Philadelphia. — 1996. — P. 149−212.
- Grochow L.B. Covalent DNA — binding drugs / In: «Chemotherapy Source Book». Ed. Π Π΅ΠΏΡ M.C. // Baltimore. 1996. — P. 293−316.
- Gupta E., Wang X., Ramirez J. et al. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and Phenobarbital // Cancer Chemother. Pharmacol. 1997. — Vol. 39. — P. 440−444.
- Hagipantelli R., Saliba F., Misset J.L. et al. Pathophysiology and therapy of irinotecan induced delayed onset diarrhea: a prospecti assessment. // ASCO. 1995. — Abstr. 1499.
- Herrmann R., Borner M., Morant R. et al. Combining Gemcitabine (GEM) and capecitabine (CAP) in advanced pancreatic cancer. Results of a phase I trial // Proc. ASCO. 2000. — Vol. 19. — P. 267 (abstr. 1038).
- Hindenburg A.A., Mattheus L. Complete and sustained remission of refractory cervical cancer following a single cycle of capecitabine. A case report. // IGCS, International Journal of Gynecological Cancer. 2003. -Vol. 13, № 6. P. 898−900.
- Judson I.R., Beale P.J., Trigo J.M. et al. A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labeled drug // Invest. New drugs. 1999. — Vol. 17. — P. 4956.
- Kanzawa F., Sugimoto Y., Minato K. et al. Establishment of a camptothecin analogue (CPT-1 l)-resistant cell line of human non-small cell lung cancer characterization and mechanism of resistance // Cancer Res. 1990. — Vol.50. — P. 5919−5924.
- Kavanagh J., Verschraegeu C., Levenback C. et. al. // Proc. ASCO. -1996.-Vol. 19.-P. 394a.-Abstr. 1561.
- Kawato Y, Aonuma M, Horota Y et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11 //Cancer Res. 1991. — Vol. 51. — P. 4187−4191.
- Kawato Y., Aonuma M., Horota Y. et al. SN-38 a metabolite of CPT-11 has a dominant role in antitumor effect of CPT-11 in cells. // 3d Conf. on DNA Topoisomerases in therapy N4. 1990. — Abstr. 63.
- Kim R., Hirabayashi N, Nishiyama M et al. Experimental studies on biochemical modulation targeting Topoisomerase I and II in human cancer xenografts in nudemice. // Proc. AACR. 1991. — Abstr. 1990.
- Kitazono M., Takebayashi Y., Ishitsuka K., et al. Prevention of hypoxia-induced apoptosis by the angiogenic factorthimidine phosphorilase // Biochem. Biophys. Res. Commun. 1998. — Vol. 253. — P. 797−803.
- Leonard R.C.F. Oral fluoropyrimidines among the new drugs for patient with metastatic breast cancer // Brit. J. Cancer. — 2001. Vol. 84. — P. 1437- 1442.
- Lira-Puerto V, Piccart M, Wiernik P, et al. A comparison of US and Mexican experience with single drug therapy in advanced cervical cancer (NCI-PAHO and ECOG study). // Proc. ASCO. 1985. — Vol. 4. — P. 117.
- Liu G., Franssen E., Fitch M., Warner E. Patient preferences for oral versus intravenous palliative care // J. Clin. Oncol. 1997. — Vol. 15. — P. 110−115.
- Liu L.F. Topoisomerase I targeting drugs mechanism of inhibition and cytotoxicity // World Conf. Clin. Pharm. And Ther. Highlihts Sat. Symp.: Appr. To Cane. Treat, by Topoisomerase I Inhib. Tokyo. — 1992. — P. 69.
- Look K.Y., Blessing J.A., Levenback C. et al. A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: A Gynecologic Oncology Group study // Gynecol Oncol. 1998. — Vol. 70. — P. 334−338.
- Mackean M., Planting A., Twelves C. et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patientswith advanced and/or metastatic cancer // J. Clin. Oncol. 1998. — Vol. 16. P. 2977−2985.
- Maeda K., Chung Y.S., Ogawa S. et al. Thymidine phosphorylase / platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma // Br. J. Cancer. 1996. — Vol. 73. -P. 884−888.
- Malkasian G, Decker D, Green S, et al. Treatment of recurrent and metastatic carcinoma of the cervix: comparison of doxorubicin with combination of vincristine and 5-fluorouracil. // Gynecol. Oncol. 1981. -Vol. 11.-P. 235−239.
- Malkasian G, Decker D, Jorgensen E. Chemotherapy of carcinoma of the cervix. // Gynecol. Oncol. 1977. — Vol.5. -P.109- 120.
- Matsuura Π’., Kuratate I., Teramachi K. et al. Thymidine phosphorylase expression is associated with both increase of intratumoral microvessels and decrease of apoptosis in human colorectal carcinomas // Cancer. Res. -1999. Vol. 59. — P. 5037−5040.
- McGuire WP, Arseneau J, Blessing JA. et al. A Randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: Gynecology Oncology Group study. // J. Clin. Oncol. 1989. — Vol. 7. — P. 1462−1468.
- Mori Π., Hasegawa M., Nishida M. et al. Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues // Int. J. Oncol. 2000. — Vol. 7. — P. 33−38.
- Muscato MS, Perry MC, Yarbo JW. Chemotherapy of cervical carcinoma. // Semin. Oncol. 1982. -Vol. 9. — P. 373−387.
- Muss HB, Bundy BN, Yazigi R, et al. Teniposidi in squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group. // Cancer Treat. Rep. 1987. — Vol. 71. — P. 873−874.
- NCIC CTC — v. 3.0 // Common Toxicity Criteria NCIC. — June 2003.
- Nishio S., Kumagai S., Hiroi N. et. all. Neoadjuvant chemotherapy with cisplatin and Π‘Π Π’ 11 for advanced cervical cancer. // Gan To Kagaku Ryoho. — 2000. — Vol. 27, № 3. — P. 429−435.
- Oken M.M., Creech R.H., Tormey D.C. et al. Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group // Am J. Clin. Oncol. 1982. — Vol. 5. — P. 649−655.
- Overmann Π., Buer J., Hoffman R. et al. Capecitabine in the treatment of metastatic renal cell carcinoma // Br. J. Cancer. 2000. — Vol. 83. — P. 583−587.
- Parkin D.M. Death from cervical cancer // Lancet. 1999. — Vol. 8484. P.797.
- Parkin D.M., Pisani P., Ferlay J. Global Cancer Statistics // Cancer J. Clin. 1999. — Vol.49, № 1. — P. 33−64.
- Payne S.A. A study of quality of life in cancer patients receiving palliative chemotherapy // Soc. Sci. Med. 1992. — Vol. 35. — P. 1505 -1509.
- Piver M, Barlow J, Xynos F. Am. // J. Obstet. Gynecol. 1978. — Vol. 131. — P.311−313. Piver M, Barlow J, Xynos F. Am. // J. Obstet. Gynecol. — 1978.-Vol. 131.-P.311−313.
- Potkuj R.K., Price F.V., Bailey H. et al. Irinotecan in advanced squamous cell carcinoma of the cervix (phase II) // Proc. ASCO. 1995. -Abstr. 785.
- Radinsky R., Aukerman S., Fidler I. The pathogenesis of cancer metastasis: relevance to biotherapy. // Principles of Cancer Biotherapy. 3d Edition. R.K. Oldham. (Ed.) -N.Y.: Kluwer Academic Publishers. 1998. P. 16−38.
- Raymond L., Menegoz F. et al.- Recent trends in incidence of cervical cancer in several regions of South-Western Europe. // Rev. Epidemiol, et Sante publ. 1995. — Vol. 43, № 2. — P. 122−126.
- Reigner Π., Goggin Π’., Jorga Π. et al. Summary of the human pharmacokinetics and biopharmaceutics of capecitabine // Res. Rep. N-139 451.- 1997.
- Rose P.G., Bundy B.N., Watkins E.B. et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. // N. Engl. J. Med. 1999. — Vol. 340. — P. 1144−1153.
- Rothenberg M.L. Topoisomerase I inhibitors: review and update // Ann. Oncol. 1997. -Vol. 8. — P.55−83.
- Sakata Y., Suzuki H., Kamataki T. Preventive effect of TJ-14, a Kampto medicine on diarrhea induced by irinotecan // Proc. ASCO. -1994.-Abstr. 1578.
- Saliba F., Hagjpantelli R., Misset J.L. et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer a prospective assessment // J. Clin. Oncol. -1998.-Vol. 16.-P. 2745−2751.
- Schilsky R.L. Pharmacology and clinical status of capecitabine. // Oncology. 2000. — Vol. 14. — P. 1297−1306.
- Schuller J., Cassidy J., Dumont E. et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients // Cancer. Chemother. Pharmacol. 2000. — Vol. 45. — № 4. — P. 291−297.
- Shraub S., Alauzet E., Schaffer P. et al. Epidemiologie descriptive des cancers gynecologiques et mammaies. // Rev. Fr. Gynecol et Obstet. -1992. — Vol. 87, № 12. — P 577−595.
- Skeel R.T. Biologic and pharmacologic basis of cancer chemotherapy / In: «Handbook of Cancer Chemotherapy». Skeel R.T., Lachant N.A. (Eds.) 1995. — P. 3−17.
- Stehman FB, Blessing JA, McGehee R, Barrett RJ, J. A phase II evaluation of mitolactol in patients with advanced squamous cellcarcinoma of the cervix: a Gynecologic Oncologic Group study// Clin. Oncol. 1989. — Vol. 7. — P. 1892−1895.
- Sugiyamo Π’., Nishida Π’., Kumagai S. et. al. Combination therapy with CPT — 11 and cisplatin and neoadjuvant chemotherapy in locally advanced cervical cancer. // Brit. J. Cancer. 1999. — Vol. 81. — P. 95−98.
- Sugiyamo Π’., Noda K., Yakushije M. et. al. Multicentric phase II trial of irinotecan (CPT 11) and as first line chemotherapy in recurrent or advanced cervical cancer: Japan CPT — 11 study group trial. // Proc. ASCO-1998.-Vol. 18.-P. 352.-Abstr. 1380.
- Sutton G.P., Blessing J.A., Photopoullos G. et al. Phase II experience with ifosfamide / mesna in gynecologic malignancies: premilinary report of Gynecology Oncology Group studies. // Semin. Oncol. 1989. — Vol. 16 (suppl 3). — P. 68−72.
- Sutton GP, Blessing JA, Adcock L, et al. Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix: A Gynecology Oncology Group study. // Invest. New drugs. 1989. — Vol. 7. -P. 341−343.
- Takebayashi Y., Akiyama S., Akiba K., et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase in human colorectal cancer // J. Natl. Cancer. Inst. 1996. — Vol. 88. — P. 1110−1117.
- Takeuchi S., Noda K., Yakushije M. et. al. Late phase II study of CPT 11 a topoisomerase I inhibitor, in advanced cervical carcinoma. // Proc. ASCO. — 1992. — Vol. 11. — P. 224. — Abstr. 708.
- Tan K.B., Mattern M.R., Eng W.K. et al. Nonproductive rearrangement of DMA topoisomerase I and n genes: correlation with resistance to topoisomerase inhibitors // J. Natl. Cancer Inst. 1989. — Vol. 81. — P. 1732−1735.
- Tanizawa A., Fujimori A., Fujimori Y., Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and citotoxity of camptothecinderivatives presently in clinical trials // J. Nat. Cane Inst. 1994. — Vol. -86. — P. 836−842.
- Thigpen J.T. / In: M.C. Perry (ed) «The chemotherapy source book». -1997. -P.1253−1288.
- Thigpen J.T. Single agent chemotherapy in carcinoma of the cervix / In: Surwit E., Albert D. (eds.) // Cervix cancer. Boston: Martinus Nijhoff. 1987.-P.l 19−136.
- Thigpen J.T., Vance R.B., Balducci Z. et al. Chemotherapy in the management of the advanced or recurrent cervical and endometrial carcinoma// Cancer. 1981. — Vol. 48. — P. 658−665.
- Thigpen Π’., Shingleton H, Honesley H. et al. Cisplatinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group // Cancer. 1981. — Vol.48. -P. 899−903.
- Thigpen Π’., Shingleton H, Honesley H. et. all. Cisdichlorodiammi-neplatinum (II) in the treatment of gynaecologic valignancies: phase II trial by the Gynecologic Oncology Group // Cancer Treat Rep. 1979. Vol. 63, № 9−10. — P. 1549−1555.
- Thigpen Π’., Shingleton H., Homesley H. et al. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix // Cancer. 1981. — Vol. 48. — P. 899−903.
- Thigpen Π’., Vance R.B., Khansur T. Carcinoma of the uterine cervix: current status and future directions. // Semin. Oncol. — 1994. Vol. 21, Suppl.2. — P.43−54.
- Toi M., Ohashi Π’., Takatsuka Y., et al. Selective effect of adjuvant 5'-deoxy-5-fluorouridine treatment for thymidine phosphorylase positivetumors in primary breast cancer. // Proc. ASCO. 1997. Vol. 16. — P.136a (abstr. 481).
- Twelves C., Glynne-Jones R., Cassidy J. et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites // Clin. Cancer Res. 1999. — Vol. 5. P. 1696−1702.
- Vasey P.A., McMahon L., Paul J. et al. A phase II trial of capecitabine (Xeloda) in relapsed ovarian cancer // Ann. Oncol. 2000. — Vol. 11. — P. 84 (abstr. 373).
- Vermorken J.B. The role of chemotherapy in squamous cell carcinoma of the uterine cervix: a review // Int. J. Gynecol. Cancer. 1993. — Vol. 3. -P. 129−142.
- Verschraegen C.F., Levy Π’., Kudelka A.P. et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix //J. Clin. Oncol. 1997. — Vol. 15. — P. 625−631.
- Wasserman E., Myara A., Lokiec F. et al. Severe CPT-11 toxicity in patients with Gilberts syndrome: two case reports // Ann. Oncol. 1997. -Vol. 8.-P. 1049−1051.
- Wasserman Π’., Carter S. The integration of chemotherapy into combined modality treatment of solid tumors. // VIII. Cervical cancer. Cancer Treat. Rev. 1977. — Vol.4.- P.25−46.
- Weidrpass E. Hormonal risk factors of cancer in humaps point of cancer epidemiologist // International Conference. Hormonal carcinogenesis. SPb. — 2000. — P. 22−23.
- Ychou M., Rougier Ph., Oberling F. et al. A phase II randomized study of CPT-11 in colorectal cancer refractory to 5-FU with prevetive treatment of delayed diarrhea using acetorphan // Proc. ASCO. 1996. — Abstr. 488.